Class 514/211.07 - Nitrogen attached directly or indirectly to the ring nitrogen of the seven-membered hetero ring by acyclic nonionic bonding (e.g., Diltiazem, etc.)

Subclass of Class 514 - Drug, bio-affecting and body treating compositions
Definition: Subject matter wherein the ring nitrogen of the seven-membered
No. of patents: 113
Last issue date: 11/01/2011

«First «Previous1 2 3 Next»Last»

Number	Title	Issue Date
8048875	Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker Bethanechol, diltiazem, or a combination thereof is administered locally to the anus for the treatment of benign anal disorders, in particular anal fissures and hemorrhoids. The agents induce a reduction in the mean and resting pressure, thereby assisting in the hea...	11/01/2011
7893050	Fasudil in combination therapies for the treatment of pulmonary arterial hypertension Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to ther...	02/22/2011
7390798	Carboxamide spirolactam CGRP receptor antagonists The present invention is directed to compounds of Formula I: I (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in...	06/24/2008
7291639	Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) This invention provides methods of inhibiting plasminogen activator inhibitor-1 (PAI-1) in a mammal, utilizing compounds of the formula: wherein: A is C or N; B is O, S, N, or CH═CH;	11/06/2007
7259250	C-nitroso compounds and use thereof A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less th...	08/21/2007
7109161	Preserved pharmaceutical formulations The present invention is directed to the use of benzethonium chloride, alone or in combination with phenoxyethanol or phenyl ethyl alcohol, to provide anti-microbial activity in pharmaceutical compositions. The present invention also provides methods of using benzet...	09/19/2006
7101909	Calcium channel drugs and uses Novel multibinding compounds are disclosed. The compounds of this invention comprise 2–10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca++ channel, thereby modulating the biological activities...	09/05/2006
7053081	Cyclic malonamides as inhibitors of A-β protein production This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor prote...	05/30/2006
7049308	C-nitroso compounds and use thereof A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less th...	05/23/2006
7041305	Stable water in oil aminophylline emulsions A water in oil emulsion system and a process for preparing such a emulsion has been provided for topically applying aminophylline for reducing cellulite conditions. ...	05/09/2006
7030110	Cyclic oxyguanidine pyrazinones as protease inhibitors Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, sol...	04/18/2006
7018649	Felodipine transdermal device and methods A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24...	03/28/2006
6984620	Preserved pharmaceutical formulations The present invention is directed to the use of benzethonium chloride, alone or in combination with phenoxyethanol or phenyl ethyl alcohol, to provide anti-microbial activity in pharmaceutical compositions. The present invention also provides methods of using benzet...	01/10/2006
6977252	Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs The present invention relates to use of compounds represented by the following general formula [1] or salts or prodrugs thereof: [where R1 represents hydrogen atom or lower alkoxy group; R2 represe...	12/20/2005
6951860	Calcium channel blockers The invention involves the identification of a family of compounds which block calcium channels. The compounds can be formulated in pharmaceutical carriers and administered to subjects. The compounds are useful for treating disorders associated with calcium channel ...	10/04/2005
6924277	Cyclized benzamide neurokinin antagonists for use in therapy Compounds having the general formula wherein R1a, R1b, R1c, X1, X2, R2, R3, R4, R5, R6, n, Y and Z are as de...	08/02/2005
6897305	Calcium channel drugs and uses Novel multibinding compounds are disclosed. The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Ca++ channel , thereby modulating the biological activities ...	05/24/2005
6864250	N-acylated lipophilic amino acid derivatives Compounds of structural Formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptabl...	03/08/2005
6759404	Cyclic malonamides as inhibitors of aβ protein production Novel cyclic malonamides having the formula (I): and their pharmaceutical compositions. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-pept...	07/06/2004
6716835	Use of diltiazem for treating retinal pathologies The invention concerns the use of a calcium channel blocker compound and/or cyclic GMP-dependent channels, namely diltiazem, for treating retinal pathologies, and more particularly retinal diseases caused by degeneration of visual receptors, in a human or animal.	04/06/2004
6624157	Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formulas ##STR1## and their enantiomers, diastereomers, and their pharmaceutically acceptable salts, including prodrugs and solvate...	09/23/2003
6610682	Pharmaceutical compositions and methods for the treatment of arteriosclerosis A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, and one or more insulin resistance improving agents...	08/26/2003
6602865	Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds Pyridazino(4,5-b)(1,5)oxazepinone, thiazepinone and diazepinone compounds of formula(I) ##STR1## and their tautomers and the acid-addition salts of all these compounds show memory-enhancing and neuroprotective properties....	08/05/2003
6579867	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ଲ-amyloid peptide release and/or its synthesis by use of such compounds Disclosed are compounds which inhibit ଲ-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits ଲ-amyloid...	06/17/2003
6559141	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ଲ-amyloid peptide release and/or its synthesis by use of such compounds Disclosed are compounds which inhibit ଲ-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits ଲ-amyloid...	05/06/2003
6544978	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ଲ-amyloid peptide release and/or its synthesis by use of such compounds Disclosed are compounds which inhibit ଲ-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits ଲ-amyloid...	04/08/2003
6541466	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ଲ-amyloid peptide release and/or its synthesis by use of such compounds Disclosed are compounds which inhibit ଲ-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits ଲ-amyloid...	04/01/2003
6514963	Methods for the inhibition of egg production in trematodes The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective amount of an agent which transiently inhibits the influx of c...	02/04/2003
6503897	Antibacterial agents Compounds of formula (I) are antibacterial agents wherein: R3 and R4, taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 16 ...	01/07/2003
6476016	Cyclic oxyguanidine pyrazinones as protease inhibitors Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: ##STR1## wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically ...	11/05/2002
6391869	Compositions and methods for the treatment of anorectal disorders Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2-) scavengers, ଲ-adrenergic agonists, cAMP-dependent protein kinase activa...	05/21/2002
6337325	Combined preparation for the therapy of immune diseases A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca2+ content, is suitable for the treatment of immunological diseases....	01/08/2002
6319915	Benzazepine derivatives as inhibitors of hyperproliferation diseases A method of treating hyperproliferation diseases in mammals in need of such treatment which method includes administering to said mammal a therapeutically effective amount of a compound of the formula: ##STR1## or a pharmaceutically acceptable salt, hydra...	11/20/2001
6284763	Methods for remodeling neuronal and cardiovascular pathways The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a met...	09/04/2001
6174917	Method of treating liver disease and like indications with vasodilating agents Liver diseases, such as cirrhosis of the liver, toxic and medicamentary liver damage, a liver-parenchymic disorder or hepatitis, are treated by administering to a human or animal subject in need thereof a therapeutically active or prophylactically effecti...	01/16/2001
6156746	1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formula ##STR1## and their enantiomers, diastereomers, and their pharmaceutically acceptable salts, including prodrugs and sol...	12/05/2000
5990103	Combination preparation for use in immunological diseases A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca2+ content, is suitable for the treatment of immunological diseases....	11/23/1999
5968925	Process for continuous sintering of granules The invention relates to a process for continuous sintering of granules for the preparation of pellets, in particular medicament formulations in tablet form....	10/19/1999
5929122	Combination preparation containing tramadol and a calcium channel antagonist A pharmaceutical combination preparation, particularly for the treatment of pain, which contains a combination of the pain killer tramadol with at least one calcium channel antagonist, and a method of treating pain by administering to a patient suffering ...	07/27/1999
5902609	Composition for the control of wound scar production This invention pertains to a composition for controlling wound scar production containing a calcium antagonist and a protein synthesis inhibitor. The method can be used to minimize wound scars, such as hypertrophic wound healing disorders keloids and burn...	05/11/1999

«First «Previous1 2 3 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Class 514/211.07 - Nitrogen attached directly or indirectly to the ring nitrogen of the seven-membered hetero ring by acyclic nonionic bonding (e.g., Diltiazem, etc.)